Company News-Bio-Thera Solutions, Ltd.

STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi

2026-02-13

• European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera ...

查看详情

07-022025

IDMC Provides Positive Recommendation for Bio-Thera Solution’s BAT4406F (ADCC-Enhanced Anti-CD20 mAb) in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Pivotal Phase II/III Trial

Guangzhou,China – July 2025 – Bio-Thera Solutions, Inc. (688177:SH), a commercial-stagebiopharmaceutical company develop...
06-252025

Bio-Thera Solutions Announces First Patient Dosed in Phase 3 Clinical Trial for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor α for the Treatment of Platinum-Resistant Ovarian Cancer

Guangzhou, China– June 25, 2025 – Bio-TheraSolutions Inc. (688177:SH), acommercial-stage biopharmaceutical company devel...
06-252025

Bio-Thera Solutions and SteinCares Expand Partnership to Commercialize Biosimilars for Treatment of Inflammatory Diseases Across Latin America

· This new agreement marksthe fourth product in the partnership and introduces a potential cost-effectivealternative to ...

上一页 ···3 4 5 6 7 ··· 下一页